• 12). B-cell chronic lymphocytic leukemia/lymphoma 6 (BCL-6) is a protein encoded by a proto-oncogene present on chromosome 3 (3q27.3) that stimulates inflammatory cytokines such as interleukin-6 (IL-6), IL-8, and IL-17 in the peritoneal fluid of people with endometriosis. (nezhat.org)
  • 1 BL tumour cells usually express IgM, 13 - 15 B-cell markers such as CD19, CD20 and CD22 and markers of germinal centre (GC) centroblasts such as CD10, BCL6 4 and the human germinal centre-associated lymphoma (HGAL) protein. (bmj.com)
  • Also, since BCL6 interacts with several co-repressor complexes to inhibit transcription, and its gene is frequently trans-located and hyper-mutated in diffuse large B cell lymphoma (DLBCL), miR-155 acts to enhance transcription and contribute to the pathogenesis of DLBCL. (biomedcentral.com)
  • The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1). (lookformedical.com)
  • They are important post-transcriptional regulators of gene expression in plants, metazoans, and mammals, and are predicted to control the activity of 30% of all protein-coding genes [ 2 ]. (biomedcentral.com)
  • [ 6 ] and grade 3B, in which folllicles composed of centrocytes are present. (medscape.com)
  • Flow cytometric analysis of Bcl-6 expression in Ramos cells. (bdbiosciences.com)
  • A fluorescence histogram showing Bcl-6 expression (or Ig Isotype control staining) was derived from gated events with the forward and side light-scatter characteristics of intact cells. (bdbiosciences.com)
  • We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test). (bdbiosciences.com)
  • From their naïve to highly differentiated effector function, T cells undergo metabolic reprogramming [ 6 ] . (encyclopedia.pub)
  • As BCL6 has been shown to modulate the STAT-dependent Interleukin 4 (IL-4) responses of B cells, miR-155 acts to increase B cell functioning. (biomedcentral.com)
  • dashed line histogram) or BD Horizon™ R718 Mouse Anti-Human Bcl-6 antibody (Cat. (bdbiosciences.com)
  • To discover B cell genes regulated by IRF8, we transfected purified primary tonsillar B cells with enhanced green fluorescent protein-tagged IRF8, generated small interfering RNA knockdowns of IRF8 expression in a mouse B cell lymphoma cell line, and examined the effects of a null mutation of IRF8 on B cells. (duke.edu)
  • ຢ່າງໃດກໍຕາມ, ມີ overexpression (ຫຼືຫຼາຍເກີນໄປ) ຂອງ ທາດໂປຼຕີນຈາກ MYC ແລະ BCL ຢູ່ໃນຈຸລັງ lymphoma. (lymphoma.org.au)
  • Kodwa-ke, kukhona i-overexpression (noma kakhulu) ye- Amaprotheni e-MYC kanye ne-BCL kumaseli e-lymphoma. (lymphoma.org.au)
  • Ku-triple hit lymphoma unokuhlela kabusha ohlotsheni lwakho lwe-MYC ne-BCL2, kodwa futhi uzoba nokuhlela kabusha kolunye ufuzo olubizwa nge-BCL6. (lymphoma.org.au)
  • Komabe, pali kuchulukirachulukira (kapena kuchulukira) kwa Mapuloteni a MYC ndi BCL pa maselo a lymphoma. (lymphoma.org.au)
  • Mu trile hit lymphoma mumakhala ndi kukonzanso mu majini anu a MYC ndi BCL2, koma mudzakhalanso ndi kukonzanso mu jini ina yotchedwa BCL6. (lymphoma.org.au)
  • Dûbele en triple hit lymfomen ferwize nei genetyske feroaringen neamd rearrangements belutsen by jo lymphoma. (lymphoma.org.au)
  • Dûbele en triple hit lymphoma ferwize nei genetyske feroarings neamd rearrangements dat kin barre yn minsken mei hege graad B-cell lymfomen. (lymphoma.org.au)
  • Heechweardige lymfomen dy't dûbele of trijefâldige hitferoarings hawwe kinne as in dûbele ekspresje omfetsje Diffuse Large B-cell Lymphoma (DLBCL) en oare heechweardige B-cell-lymfomen. (lymphoma.org.au)
  • De feroaring dy't bart yn dizze genen wurdt in weryndieling neamd en kin jo kâns fergrutsje om lymphoma te krijen en it yn guon gefallen dreger te meitsjen. (lymphoma.org.au)
  • Yn triple hit lymphoma jo hawwe in weryndieling yn jo MYC en BCL2 genen, mar jo sille ek hawwe in werrangearring yn in oar gen neamd BCL6. (lymphoma.org.au)
  • Dûbele hit lymphoma ferwiist allinich nei oft jo in weryndieling hawwe yn jo MYC en jo BCL2-genen. (lymphoma.org.au)
  • Oft jo lymphoma kin wurde genêzen, of hoe wierskynlik it is om werom te kommen (weromkomme) nei behanneling, hinget ôf fan alle ferskillende genetyske feroaringen en aaiwiten belutsen by jo yndividuele lymphoma en ek oare faktoaren. (lymphoma.org.au)
  • Sprek mei jo dokter oer jo yndividuele feroaringen en wat dizze betsjutte foar jo lymphoma en behannelingopsjes. (lymphoma.org.au)
  • Duk da haka, akwai overexpression (ko da yawa) na MYC da BCL sunadaran a kan ƙwayoyin lymphoma. (lymphoma.org.au)
  • A cikin nau'in lymphoma sau uku kuna da sake tsarawa a cikin kwayoyin halittar ku na MYC da BCL2, amma kuma za ku sami sake tsarawa a cikin wani kwayar halitta mai suna BCL6. (lymphoma.org.au)
  • Gayunpaman, mayroong labis na pagpapahayag (o labis) ng Mga protina ng MYC at BCL sa mga selula ng lymphoma. (lymphoma.org.au)
  • Sa triple hit lymphoma mayroon kang muling pagsasaayos sa iyong MYC at BCL2 genes, ngunit magkakaroon ka rin ng muling pagsasaayos sa isa pang gene na tinatawag na BCL6. (lymphoma.org.au)
  • Bisan pa, adunay sobra nga pagpahayag (o sobra) sa Mga protina sa MYC ug BCL sa mga selula sa lymphoma. (lymphoma.org.au)
  • Sa triple hit lymphoma ikaw adunay usa ka rearrangement sa imong MYC ug BCL2 nga mga gene, apan ikaw usab adunay usa ka rearrangement sa laing gene nga gitawag og BCL6. (lymphoma.org.au)
  • Leha ho le joalo, ho na le maikutlo a feteletseng (kapa a mangata haholo) a Liprotheine tsa MYC le BCL liseleng tsa lymphoma. (lymphoma.org.au)
  • Ho triple hit lymphoma u na le tlhophiso bocha liphatseng tsa hau tsa MYC le BCL2, empa hape u tla ba le tlhophiso bocha ho mofuta o mong o bitsoang BCL6. (lymphoma.org.au)
  • Heoi, he nui te whakahua (he nui rawa ranei) o te MYC me BCL pūmua i runga i nga pūtau lymphoma. (lymphoma.org.au)
  • I roto i te lymphoma e toru kua pa ki a koe he whakarereketanga i o ira MYC me BCL2, engari ka whai whakarereke ano koe i tetahi atu ira e kiia nei ko BCL6. (lymphoma.org.au)
  • Ae ui i lea, o loʻo i ai se faʻamatalaga (pe tele naua) o le MYC ma BCL polotini i luga o sela lymphoma. (lymphoma.org.au)
  • I le triple hit lymphoma e iai sau toe fetuutuunai i au kenera MYC ma BCL2, ae o le a iai foi sau toe fetuutuunai i se isi kenera e ta'ua o le BCL6. (lymphoma.org.au)
  • Immunoglobulin heavy chain (IGH), B cell lymphoma (BCL)2, BCL6 and MYC were rearranged in 71%, 11%, 12% and 18% cases, respectively. (ntu.edu.tw)
  • PATIENTS AND METHODS: Paraffin-embedded lymphoma samples from 193 patients with de novo DLBCL who were uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were studied using immunohistochemistry for MYC, BCL2, CD10, BCL6, and MUM1/interferon regulatory factor 4, and fluorescent in situ hybridization (FISH) for MYC and BCL2. (duke.edu)
  • Interferon (IFN) consensus sequence-binding protein/IFN regulatory factor 8 (IRF8) is a transcription factor that regulates the differentiation and function of macrophages, granulocytes, and dendritic cells through activation or repression of target genes. (duke.edu)
  • Chromatin immunoprecipitation studies demonstrated in vivo occupancy of 5' sequences of both genes by IRF8 protein. (duke.edu)
  • 2. Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes. (nih.gov)
  • ການຈັດລຽງສິ່ງເຫຼົ່ານີ້ເກີດຂຶ້ນໃນ genes ເອີ້ນວ່າ MYC ແລະ BCL ທີ່ຮັບຜິດຊອບໃນການຄວບຄຸມການຂະຫຍາຍຕົວແລະການຄວບຄຸມຂອງ lymphocytes B-cell, ລວມທັງເວລາທີ່ພວກມັນຄວນຈະຖືກທໍາລາຍ. (lymphoma.org.au)
  • Idan kana da DHL ko THL, kwayoyin halitta (MYC da BCL genes) akan chromosomes an sake tsara su. (lymphoma.org.au)
  • Kung mayroon kang DHL o THL, ang mga gene (MYC at BCL genes) sa iyong mga chromosome ay muling inayos. (lymphoma.org.au)
  • Afai e iai sau DHL po'o THL, o kenera (MYC ma BCL genes) i au chromosomes ua toe fa'atulaga. (lymphoma.org.au)
  • Evolutionary studies have demonstrated that the increase in organisms complexity corresponds to a decrease in the abundance of protein-coding genes and a concomitant rise in the number of ncRNAs, indicating that regulatory RNA diversification has been critical to increase vertebrate complexity ( 15 , 16 ). (frontiersin.org)
  • This study examined the involvement of three genes- bcl-2, bcl-6 , and bcl-10 -in PIOL cells. (arvojournals.org)
  • 5. Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD. (nih.gov)
  • 15. Densely methylated DNA traps Methyl-CpG-binding domain protein 2 but permits free diffusion by Methyl-CpG-binding domain protein 3. (nih.gov)
  • MYC proto-oncogene (MYC) and Epstein-Barr encoding mRNA (EBER) were positive in 43% (nine of 21) and 17% (four of 23) cases, respectively. (ntu.edu.tw)
  • This study examined the expression of the bcl-2 t(14;18) translocation, the bcl-10 gene, and high expression of bcl-6 mRNA in PIOL cells. (arvojournals.org)
  • Microdissection and PCR analysis were used to examine vitreous specimens in patients with PIOL for the presence of bcl-2 t(14;18) translocations, the bcl-10 gene, and expression of bcl-6 mRNA. (arvojournals.org)
  • The bcl-10 gene was detected in 6 of 26 (23%) patients, whereas 4 of 4 (100%) PIOL patients expressed higher levels of bcl-6 mRNA compared with inflammatory lymphocytes. (arvojournals.org)
  • Anemarsaponin B decreases the protein and mRNA levels of iNOS and COX-2 . (medchemexpress.com)
  • Zosintha izi zimachitika mkati majini otchedwa MYC ndi BCL omwe ali ndi udindo woyang'anira kukula ndi kulamulira kwa B-cell lymphocytes, kuphatikizapo pamene ayenera kuwonongedwa. (lymphoma.org.au)
  • Waɗannan sake tsarawa suna faruwa a ciki kwayoyin halittar da ake kira MYC da BCL waɗanda ke da alhakin tsara girma da sarrafa ƙwayoyin lymphocytes B-cell, ciki har da lokacin da ya kamata a lalata su. (lymphoma.org.au)
  • Ang mga pagbabagong ito ay nangyayari sa mga gene na tinatawag na MYC at BCL na may pananagutan sa pag-regulate ng paglaki at pagkontrol ng mga B-cell lymphocytes, kasama na kung kailan dapat sirain ang mga ito. (lymphoma.org.au)
  • Ka puta enei whakatikatika i roto ira e kiia ana ko MYC me BCL kei a raatau te kawenga mo te whakahaere i te tipu me te whakahaere o nga lymphocytes pūtau-B, tae atu ki te wa e tika ana kia whakangaromia. (lymphoma.org.au)
  • O nei suiga e tupu i totonu kenera e ta'ua o le MYC ma le BCL e nafa ma le faʻatonutonuina o le tuputupu aʻe ma le puleaina o lymphocytes B-cell, e aofia ai le taimi e tatau ai ona faʻaumatia. (lymphoma.org.au)
  • Mena kei a koe te DHL, THL ranei, ko nga ira (MYC me BCL ira) kei o chromosomes kua whakarereketia. (lymphoma.org.au)
  • Uma une-DHL noma i-THL, izakhi zofuzo (i-MYC ne-BCL) kuma-chromosome akho zihlelwe kabusha. (lymphoma.org.au)
  • Ngati muli ndi DHL kapena THL, majini (majini a MYC ndi BCL) pa ma chromosome anu asinthidwanso. (lymphoma.org.au)
  • Kung ikaw adunay DHL o THL, ang mga gene (MYC ug BCL nga mga gene) sa imong mga chromosome gibag-o. (lymphoma.org.au)
  • Haeba u na le DHL kapa THL, liphatsa tsa lefutso (liphatsa tsa lefutso tsa MYC le BCL) li-chromosome tsa hau li hlophisitsoe bocha. (lymphoma.org.au)
  • Bcl-2 is an antiapoptotic molecule whose gene is located on chromosome 18. (arvojournals.org)
  • 14. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. (nih.gov)
  • PIOL has unique molecular patterns of bcl-2, bcl-10 , and bcl-6 when compared with other systemic lymphomas. (arvojournals.org)
  • Scholars@Duke publication: Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. (duke.edu)
  • 9. Zinc finger transcription factor CASZ1 interacts with histones, DNA repair proteins and recruits NuRD complex to regulate gene transcription. (nih.gov)
  • Kini nga mga pag-usab mahitabo sa mga gene nga gitawag og MYC ug BCL nga responsable sa pag-regulate sa pagtubo ug pagkontrol sa mga B-cell lymphocyte, lakip na kung kanus-a kini kinahanglan laglagon. (lymphoma.org.au)
  • Although cancer prognosis has historically been based on clinical and laboratory findings, analysis of the expression of various gene translocations and proteins has burgeoned as a method for determining prognosis. (arvojournals.org)
  • The bcl-2 t(14;18) translocation brings the bcl-2 gene under the control of the IgH enhancer, resulting in deregulated bcl-2 expression. (arvojournals.org)
  • The lateral groove motif in the BTB domain of BCL6 interacts with the BBD motif of SMRT. (uth.edu)
  • Each approach identified activation-induced cytidine deaminase (AICDA) and BCL6 as targets of transcriptional activation. (duke.edu)
  • These results suggest previously unappreciated roles for IRF8 in the transcriptional regulation of B cell GC reactions that include direct regulation of AICDA and BCL6. (duke.edu)
  • 6. MBD3L1 is a transcriptional repressor that interacts with methyl-CpG-binding protein 2 (MBD2) and components of the NuRD complex. (nih.gov)
  • 11. Eukaryotic translation initiator protein 1A isoform, CCS-3, enhances the transcriptional repression of p21CIP1 by proto-oncogene FBI-1 (Pokemon/ZBTB7A). (nih.gov)
  • The efficacy of macrophage-mediated inflammatory responses relies on the coordinated expression of key proteins involved in macrophage activation and polarization processes, whose expression is finely regulated at both transcriptional and post-transcriptional levels ( 4 - 9 ). (frontiersin.org)
  • 1. The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRD-HDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation. (nih.gov)
  • BCL6 interacts with the CCL3 promoter region. (uth.edu)
  • BCL6 interacts with Mi2. (uth.edu)
  • PPAR-delta interacts with BCL-6. (uth.edu)
  • Generally, functional enhancers are binding by monomethylation at lysine 4 (K4me1), acetylation at lysine 27 (K27 ac), and absent of trimethylation at lysine 4 (K4me3) of the histone H3 protein [ 5 , 6 ]. (biomedcentral.com)
  • Fil-limfoma triple hit għandek riarranġament fil-ġeni MYC u BCL2 tiegħek, iżda jkollok ukoll riarranġament f'ġene ieħor imsejjaħ BCL6. (lymphoma.org.au)
  • Nan lenfom trip frape ou gen yon rearanjman nan jèn MYC ak BCL2 ou, men w ap genyen tou yon rearanjman nan yon lòt jèn ki rele BCL6. (lymphoma.org.au)
  • Në limfomën e goditjes së trefishtë keni një rirregullim në gjenet tuaja MYC dhe BCL2, por gjithashtu do të keni një rirregullim në një gjen tjetër të quajtur BCL6. (lymphoma.org.au)
  • Di lîmfoma sê-hitanê de we di genên xwe yên MYC û BCL2 de vesazkirinek heye, lê hûn ê di genek din a bi navê BCL6 de jî vesazkirinek hebe. (lymphoma.org.au)
  • We tested whether DLBCLs with high expression of MYC protein and BCL2 protein share the clinical features and poor prognosis of DHLs. (duke.edu)
  • The DHS-2 group, defined by high expression of both MYC and BCL2 protein, comprised 29% of the patients. (duke.edu)
  • Lykwols, der is in overexpression (of tefolle) fan de MYC en BCL aaiwiten op lymfoomsellen. (lymphoma.org.au)
  • Protein kinase affinity probe 1 is a novel protein kinase affinity probe for the functional identification of protein kinases (PKs) . (medchemexpress.com)
  • Protein kinase affinity probe 1 is a modified Purvalanol B (HY-18299) probe with 50% beads loading (Compound S3). (medchemexpress.com)
  • PknB-IN-2 (Compound 10) is a Mycobacterium tuberculosis protein kinase B ( PknB ) inhibitor with an IC 50 of 12.1 μM. (medchemexpress.com)
  • MS5033 is a potent PROTAC-based AKT ( protein kinase B) degrader, with a DC 50 of 430 nM in PC3 cells. (medchemexpress.com)
  • Anemarsaponin B also inhibits the phosphorylation of MAP kinase kinases 3/6 (MKK3/6) and mixed lineage kinase 3 (MLK3). (medchemexpress.com)
  • Cdc7-IN-5 (compound I- B ) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I- B . Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle. (medchemexpress.com)
  • B -Raf IN 5 (compound 3 b ) is a potent inhibitor of protein kinase B-Raf with an IC 50 of 2.0 nM. (medchemexpress.com)
  • OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase ) inhibitor with an IC 50 of 28 nM. (medchemexpress.com)
  • Cancer cells acquire super-enhancers at oncogene and cancerous phenotype relies on these abnormal transcription propelled by SEs. (biomedcentral.com)
  • TF binding to enhancers recruits coactivators, such as mediator (MED) complexes, CREB-binding protein (CBP), and p300. (biomedcentral.com)
  • Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6. (medchemexpress.com)
  • This protein contains an amino-terminal, protein-protein interaction BTB/POZ domain and a carboxyl-terminal DNA-binding C 2 H 2 zinc finger domain[ 2 ]. (biomedcentral.com)
  • A medical record review was also conducted to determine whether the bcl-2 t(14;18) translocation correlated with prognosis. (arvojournals.org)
  • Forty of 72 (55%) PIOL patients expressed the bcl-2 t(14;18) translocation at the major breakpoint region. (arvojournals.org)
  • An analysis of clinical outcome in 23 PIOL patients revealed no significant association between bcl-2 t(14;18) translocations and survival or relapse. (arvojournals.org)
  • This interaction was modelled on a demonstrated interaction between mouse PPAR-delta and human BCL-6. (uth.edu)
  • Dûbele hit (DHL) en triple hit (THL) lymfomen binne as jo in heechweardige lymfom hawwe en in feroaring yn jo twa (dûbele hit) of trije (trije hit) fan jo genen. (lymphoma.org.au)
  • It waard eartiids tocht dat it hawwen fan triple hit lymfoom slimmer wie as it hawwen fan dûbele hit lymfoom, en dat triple hit wie agressiver en hurder te behanneljen. (lymphoma.org.au)
  • Yn feite suggerearret de Wrâldsûnensorganisaasje (WHO) dat triple hit lymfomen net langer wurde beskôge as in aparte konsideraasje, en wurde beheard op deselde manier as in dûbel hit lymfoom wurdt beheard. (lymphoma.org.au)
  • 18. Functional characterization of the interactions between endosomal adaptor protein APPL1 and the NuRD co-repressor complex. (nih.gov)
  • 5 6 7 8 9 Because the clinical presentation often mimics uveitis, PIOL is considered a masquerade syndrome, and diagnosis requires pathologic confirmation, usually by vitrectomy. (arvojournals.org)
  • ROCK-IN-5 (compound I- B -37) is a potent inhibitor of ROCK , ERK , GSK , and AGC protein kinases . (medchemexpress.com)
  • 6 Department of Cancer Prevention, 71067Sun Yat-sen University Cancer Center, Guangzhou, China. (nih.gov)
  • B -Raf IN 6 has the potential for the research of cancer disease. (medchemexpress.com)